Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies
- 8 January 2007
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 136 (5), 699-712
- https://doi.org/10.1111/j.1365-2141.2006.06465.x
Abstract
The prevalence of hepatitis B virus (HBV) infection in patients with haematological malignancies is increased compared with the general population worldwide. HBV reactivation is common following chemotherapy and is associated with a high mortality despite prompt anti-viral treatment. HBV reactivation may necessitate interruption of chemotherapy with adverse prognostic consequences for the haematological disease. Chemotherapy-induced immune suppression may lead to increased HBV replication. Immune reconstitution within the weeks and months following recovery from chemotherapy may be associated with a flare of hepatitis B manifested by hepatocellular injury. Risk factors associated with HBV reactivation include detectable hepatitis B surface antigen (HBsAg), HBV DNA, Hepatitis B e (HBeAg) antigen, antibodies to hepatitis B core antigen (anti-HBc), treatment with corticosteroids, young age and male gender. Lamivudine is effective during HBV reactivation due to immune suppression. Clinical trials have demonstrated that pre-emptive antiviral treatment with lamivudine is superior to deferred treatment. Current recommendations emphasise screening for HBV infection in all haematology patients, particularly prior to chemotherapy. Patients who are HBsAg positive or HBV DNA positive should receive pre-emptive treatment with lamivudine before chemotherapy. The duration of lamivudine treatment may be prolonged commensurate with the degree of immunosuppression. HBV naïve patients should be immunised against hepatitis B, as should haematopoietic stem cell donors. In summary, overt and occult HBV pose a serious, but preventable, threat. Pre-treatment screening of patients at risk should be practiced diligently by all clinicians that treat patients with malignancies.Keywords
This publication has 101 references indexed in Scilit:
- Natural history of chronic hepatitis B in co-infected patientsJournal of Hepatology, 2006
- Immune Suppression as the Etiology of Failure To Detect Anti-HBc Antibodies in Patients with Chronic Hepatitis B Virus InfectionJournal of Clinical Microbiology, 2006
- Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1HJournal of Clinical Virology, 2006
- Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategiesAnnals Of The Rheumatic Diseases, 2006
- Hepatitis B virus genotypes, core gene variability and ethnicity in the Pacific regionJournal of Hepatology, 2004
- Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantationBone Marrow Transplantation, 2004
- Hepatitis B vaccinesJournal of Hepatology, 2003
- Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host diseaseBone Marrow Transplantation, 2002
- Transplantation of hepatitis B immune lymphocytes as means for adoptive transfer of immunity to hepatitis B virusJournal of Hepatology, 1995
- Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infectionJournal of Hepatology, 1990